Angiogenesefaktoren versus Doppler follow-up in der Prädiktion von schlechtem Outcome bei small-for-gestational-age Feten im dritten Trimenon

2013 ◽  
Vol 217 (S 01) ◽  
Author(s):  
SM Lobmaier ◽  
F Figueras ◽  
JU Ortiz ◽  
F Crispi ◽  
E Gratacós
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age

scholarly journals Small for Gestational Age Moderate to Late Preterm Children: A Neuropsychological Follow-up

2021 ◽  
pp. 1-11
Author(s):  
Garazi Labayru ◽  
Jone Aliri ◽  
Andrea Santos ◽  
Ane Arrizabalaga ◽  
María Estevez ◽  
...  
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age ◽  
Late Preterm ◽  
Preterm Children

Longitudinal follow-up of height up to five years of age in infants born preterm small for gestational age; comparison to full-term small for gestational age infants

2007 ◽  
Vol 83 (5) ◽  
pp. 327-333 ◽  
Author(s):  
Kazuo Itabashi ◽  
Jun Mishina ◽  
Hiroshi Tada ◽  
Motoichiro Sakurai ◽  
Yuko Nanri ◽  
...  
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age ◽  
Full Term

scholarly journals Heart Failure in Women With Hypertensive Disorders of Pregnancy

Hypertension ◽  
2020 ◽  
Vol 76 (5) ◽  
pp. 1506-1513 ◽  
Author(s):  
Michael C. Honigberg ◽  
Hilde Kristin Refvik Riise ◽  
Anne Kjersti Daltveit ◽  
Grethe S. Tell ◽  
Gerhard Sulo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Preterm Delivery ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Gestational Hypertension ◽  
Hazard Ratio ◽  
Hypertensive Disorders Of Pregnancy ◽  
First Birth ◽  
Hypertensive Disorders

Hypertensive disorders of pregnancy (HDP) have been associated with heart failure (HF). It is unknown whether concurrent pregnancy complications (small-for-gestational-age or preterm delivery) or recurrent HDP modify HDP-associated HF risk. In this cohort study, we included Norwegian women with a first birth between 1980 and 2004. Follow-up occurred through 2009. Cox models examined gestational hypertension and preeclampsia in the first pregnancy as predictors of a composite of HF-related hospitalization or HF-related death, with assessment of effect modification by concurrent small-for-gestational-age or preterm delivery. Additional models were stratified by final parity (1 versus ≥2 births) and tested associations with recurrent HDP. Among 508 422 women, 565 experienced incident HF over a median 11.8 years of follow-up. After multivariable adjustment, gestational hypertension in the first birth was not significantly associated with HF (hazard ratio, 1.41 [95% CI, 0.84–2.35], P =0.19), whereas preeclampsia was associated with a hazard ratio of 2.00 (95% CI, 1.50–2.68, P <0.001). Among women with HDP, risks were not modified by concurrent small-for-gestational-age or preterm delivery ( P interaction =0.42). Largest hazards of HF were observed in women whose only lifetime birth was complicated by preeclampsia and women with recurrent preeclampsia. HF risks were similar after excluding women with coronary artery disease. In summary, women with preeclampsia, especially those with one lifetime birth and those with recurrent preeclampsia, experienced increased HF risk compared to women without HDP. Further research is needed to clarify causal mechanisms.

scholarly journals Genetic Screening for Growth Hormone Therapy in Children Small for Gestational Age: So Much to Consider, Still Much to Discover

2021 ◽  
Vol 12 ◽  
Author(s):  
Claudio Giacomozzi
Keyword(s):  
Growth Hormone ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Genetic Screening ◽  
Adult Height ◽  
Recombinant Human Growth Hormone ◽  
Early Years ◽  
Current Evidence

Children born small for gestational age (SGA), and failing to catch-up growth in their early years, are a heterogeneous group, comprising both known and undefined congenital disorders. Care for these children must encompass specific approaches to ensure optimal growth. The use of recombinant human growth hormone (rhGH) is an established therapy, which improves adult height in a proportion of these children, but not with uniform magnitude and not in all of them. This situation is complicated as the underlying cause of growth failure is often diagnosed during or even after rhGH treatment discontinuation with unknown consequences on adult height and long-term safety. This review focuses on the current evidence supporting potential benefits from early genetic screening in short SGA children. The pivotal role that a Next Generation Sequencing panel might play in helping diagnosis and discriminating good responders to rhGH from poor responders is discussed. Information stemming from genetic screening might allow the tailoring of therapy, as well as improving specific follow-up and management of family expectations, especially for those children with increased long-term risks. Finally, the role of national registries in collecting data from the genetic screening and clinical follow-up is considered.

Longitudinal follow-up of growth in children born small for gestational age

1993 ◽  
Vol 82 (5) ◽  
pp. 438-443 ◽  
Author(s):  
K Albertsson-Wikland ◽  
G Wennergren ◽  
M Wennergren ◽  
G Vilbergsson ◽  
S Rosberg
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age

scholarly journals Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age

2021 ◽  
Vol 12 ◽  
pp. 204201882110131
Author(s):  
Mieczyslaw Walczak ◽  
Mieczyslaw Szalecki ◽  
Gerd Horneff ◽  
Jan Lebl ◽  
Barbara Kalina-Faska ◽  
...  
Keyword(s):  
Adverse Events ◽  
Carbohydrate Metabolism ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Follow Up Study ◽  
Short Children ◽  
Rhgh Treatment ◽  
Phase Iv

Background: Recombinant human growth hormone (rhGH) therapy can affect carbohydrate metabolism and lead to impaired glucose tolerance during treatment. In addition, short children born small for gestational age (SGA) are predisposed to metabolic abnormalities. This study assessed the long-term safety of rhGH (Omnitrope®) use in short children born SGA. Methods: This was a follow-up observational study of patients from a phase IV study. The baseline visit was the final visit of the phase IV study. Further visits were planned after 6 months (F1), 1 year (F2), 5 years (F3), and 10 years (F4). The primary objective was to evaluate the long-term effect of rhGH treatment on the development of diabetes mellitus; secondary objectives included incidence/severity of adverse events (AEs). Results: In total, 130 subjects were enrolled in the follow-up study; 99 completed F1, 88 completed F2, and 13 completed F3 (no subject reached F4). The full analysis set for evaluation comprised 118 patients (64 female). Mean (standard deviation) duration of follow up was 39.6 (24.4) months. No subject was newly diagnosed with diabetes. The results for carbohydrate metabolism parameters were consistent with this finding. A total of 144 AEs were reported in 54 subjects; these were mostly of mild-to-moderate intensity (96.5%) and not suspected to be related to previous rhGH treatment (94.4%). Serious AEs ( n = 18) were reported in eight patients; three (in one patient) were suspected as possibly related to previous rhGH treatment (anemia, menorrhagia, oligomenorrhoea). One fatal event occurred (sepsis), which was judged as not related to previous rhGH treatment. Conclusions: None of the participating subjects, who had all been previously treated with Omnitrope® in a phase IV study, developed diabetes during this follow-up study. In addition, no other unexpected or concerning safety signals were observed.

scholarly journals Kangaroo Mother Care –Differences and Quantitative Benefits in Different Subgroups of Low Birth Weight Babies

2020 ◽  
Vol 5 (1) ◽  
Keyword(s):  
Weight Gain ◽  
Birth Weight ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Head Circumference ◽  
Cost Effective ◽  
Kangaroo Mother Care ◽  
Daily Weight Gain ◽  
At Home

Objectives: To determine the effectiveness of Kangaroo Mother Care in subgroups of LBW babies-Preterm AGA, Preterm SGA and Term SGA, To assess any differences in benefits of KMC in relation to duration in the subgroups, To assess weight gain difference in NICU and at home at first follow up visit and up to 40 weeks of follow up to Preterm AGA, Preterm SGA and till gain of 2500g in Term SGA babies. Study design: Prospective observational study. Setting: NICU in a large teaching institute, department of pediatrics, Mahatma Gandhi Memorial Hospital, North Telangana. Subjects and Methods: 240 neonates with birth weight <2500g, hemodynamically stable. Intervention: The subjects are classified into three subgroups-based on gestational age (by new Ballard’s score) and by weight (Lubchenco’ s charts) into Preterm Appropriate for gestational age (PT AGA) (102), Preterm Small for Gestational Age (PT SGA) (88) and Term Small for Gestational age (T SGA) (50). Further categorized into <=32 wks,33-34wks,35- 36wks,>=37wks.KMC was given to all subgroups at hospital and home with mean duration of 9+2hrs at hospital and 5+2hrs at home. Outcome Measures: Growth measured by average daily weight gain, mean weight gain, (weight was measured by electronic weighing scale (seca), head circumference (measured by non-stretchable and non-metallic tape) and total length (measured by infant meter) in follow up to 40 weeks of corrected gestational age in Preterm and up to gain of 2500g in Term SGA were assessed with KMC. Results: Better weight gain was noticed in all the 3 subgroups of LBW neonates with KMC at hospital and home. In spite of lower duration of KMC at home PT AGA (33-34 weeks) subgroup has the highest weight gain (24.5+5.5g/day, p=0.003), highest head circumference gain (0.70+0.5cm/week, p=0.002), highest length gain (0.90+0.6cm/week, p <0.008). The time taken to reach full feeds and the time to reach initiation of direct breastfeeds were comparable in all subgroups but attained much earlier in PT AGA (33-34wks) and PT AGA (35-36wks). Duration of hospital stay is least in PT AGA with mean of 12.68 ± 6.37 days.KMC significantly reduced the incidence of apnea in all subgroups of LBW babies. All babies were on exclusive breastfeeds at the end of the study (98%). Conclusion: We conclude by this present study that KMC improves growth in all sub groups of LBW infants. KMC has significantly reduced the incidence of co mortifies like apnea, hypothermia, hypoglycemia in all the subgroups of LBW babies. KMC is cost effective, easily accessible and acceptable not only to mothers but also by majority of the family members

scholarly journals Consequences of Being Born Small for Gestational Age on Body Composition: An 8-Year Follow-Up Study

2008 ◽  
Vol 93 (10) ◽  
pp. 3804-3809 ◽  
Author(s):  
Taly Meas ◽  
Samia Deghmoun ◽  
Priscilla Armoogum ◽  
Corinne Alberti ◽  
Claire Levy-Marchal
Keyword(s):  
Body Composition ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Follow Up Study

scholarly journals Respiratory morbidity at follow-up of small-for-gestational-age infants born very prematurely

2012 ◽  
Vol 73 (1-4) ◽  
pp. 457-463 ◽  
Author(s):  
Janet L. Peacock ◽  
Jessica W. Lo ◽  
Walton D’Costa ◽  
Sandra Calvert ◽  
Neil Marlow ◽  
...  
Keyword(s):  
Gestational Age ◽  
Small For Gestational Age ◽  
Respiratory Morbidity
Sign in / Sign up

Export Citation Format

Share Document